Listen
ANTILYMPHOCYTE GLOBULINS FRESENIUS
-
Opinions on drugs -
Posted on
Mar 19 2013
Reason for request
Inclusion for hospital use in the extension of indication: "Conditioning before HSC (Haemopoietic Stem Cell) transplantation. -Prevention of graft versus host disease after allogenic HSC transplant. This medicinal product is indicated for use particularly in stem cell transplantation from unrelated volunteer donors in combination with standard treatments for malignant haematological disorders.”
-
Clinical Benefit
| Substantial |
The actual benefit of the proprietary medicinal product is substantial. |
Clinical Added Value
| no clinical added value |
In the absence of a comparison with THYMOGLOBULIN, a rabbit anti-thymocyte immunoglobulin and the comparison medicinal product, ANTILYMPHOCYTE GLOBULINS FRESENIUS does not offer an improvement in actual benefit (IAB V) when used for conditioning for haemopoietic stem cell transplantation or to prevent graft versus host disease after allogenic haemopoietic stem cell transplantation. |
English version
Contact Us
Évaluation des médicaments
